Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOX: Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal/Gastroesophageal Junction Adenocarcinoma
NCT06078709Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Nov 2023
- Primary completion
- May 2029
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, folinic acid, oxaliplatin in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Mayo Clinic. Started Nov 2023; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatin
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06078709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078709.